We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.025 | -1.59% | 1.55 | 1.50 | 1.60 | 1.575 | 1.55 | 1.575 | 660,833 | 09:33:29 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.30 | 12.02M |
From May 2019 to May 2024
TIDMSTX TIDMSTXW
RNS Number : 2046Z
Shield Therapeutics PLC
13 March 2017
Shield Therapeutics plc
("Shield" or the "Group")
Notice of Results
London, UK, 13 March 2017: Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on the development and commercialisation of late-stage pharmaceuticals that address unmet medical needs in secondary care, announces it will report its audited results for the year ended 31 December 2016 on Tuesday 4 April 2017.
CEO, Carl Sterritt, and members of the management team will host a presentation and live conference call for analysts at 9.30am BST on the morning of the results in the Guildhall Room at 85 Gresham Street, London, EC2V 7NQ.
- Ends -
For further information please contact:
Shield Therapeutics plc +44 (0)20 7186 8500 Carl Sterritt, Chief Executive Officer Nominated Adviser and Broker Liberum Capital Limited Christopher Britton/Steve Pearce +44 (0)20 3100 2222 Financial PR Advisor +44 (0)20 3709 5700 Consilium Strategic Communications shieldtherapeutics@consilium-comms.com Mary-Jane Elliott/Matthew Neal
About Shield Therapeutics plc
Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Group has a marketed product, Feraccru(R), for the treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD) which has exclusive IP rights until 2034. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NORBRGDXUXBBGRG
(END) Dow Jones Newswires
March 13, 2017 03:01 ET (07:01 GMT)
1 Year Shield Therapeutics Chart |
1 Month Shield Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
